Urogen Pharma (URGN)

Urogen Pharma (URGN) Income Statement


Urogen Pharma Income Statement

Last quarter (Q3 2023), Urogen Pharma's total revenue was $20.85M, an increase of 29.54% from the same quarter last year. In Q3, Urogen Pharma's net income was $-21.88M. See Urogen Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
$ 77.28M$ 64.36M$ 48.04M$ 11.80M$ 18.00K$ 1.13M
Cost of Revenue
$ 282.00K$ 7.65M$ 5.16M$ 1.01M$ 0.00$ 1.80M
Gross Profit
$ 67.94M$ 56.70M$ 42.88M$ 10.79M$ 18.00K$ -675.00K
Operating Expense
$ 87.17M$ 135.74M$ 135.18M$ 137.53M$ 109.50M$ 76.50M
Operating Income
$ -12.26M$ -79.04M$ -92.29M$ -126.74M$ -109.48M$ -77.18M
Net Non Operating Interest Income Expense
$ -13.95M$ -7.43M$ 212.00K$ 1.63M$ 4.33M$ 1.87M
Other Income Expense
$ -71.00K$ -72.00K$ -212.00K-$ -284.00K$ -224.00K
Pretax Income
$ -104.34M$ -108.03M$ -109.37M$ -125.11M$ -105.15M$ -75.53M
Tax Provision
$ 755.00K$ 1.75M$ 1.45M$ 3.37M$ 0.00$ 125.00K
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -27.25M$ -88.22M$ -110.82M$ -128.48M$ -105.15M$ -75.66M
Basic EPS
$ -4.26$ -4.81$ -4.96$ -5.90$ -5.12$ -4.80
Diluted EPS
$ -3.01$ -4.81$ 0.00$ -5.90$ -5.12$ -4.80
Basic Average Shares
$ 101.85M$ 22.81M$ 22.35M$ 21.78M$ 20.53M$ 15.75M
Diluted Average Shares
$ 79.04M$ 22.81M$ 22.35M$ 21.78M$ 20.53M$ 15.75M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 87.45M$ 143.40M$ 140.33M$ 138.54M$ 109.50M$ 78.31M
Net Income From Continuing And Discontinued Operation
$ -105.10M$ -109.78M$ -110.82M$ -128.48M$ -105.15M$ -75.66M
Normalized Income
$ -38.48M$ -77.69M-$ -128.48M$ -105.15M$ -75.58M
Interest Expense
$ -90.39M$ -99.59M$ -92.08M$ -126.74M$ -109.48M$ -77.18M
$ -52.17M$ -96.52M$ -89.83M$ -124.69M$ -108.15M$ -76.76M
Currency in USD

Urogen Pharma Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis